Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGT1A1 and MTHFR polymorphisms and irinotecan-based chemotherapy sensitivity in colorectal cancer
ChiCTR-CCH-08000114Phase 4Completed
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Oct 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Fatality rate and Survival time. Started Oct 2007; status: completed.
02
Drugs
irinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-CCH-08000114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-CCH-08000114.